Biomerica (BMRA) vs NeuroOne Medical Technologies (NMTC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Biomerica (BMRA) has outperformed NeuroOne Medical Technologies (NMTC) over the past year, losing 34.4% versus a loss of 82.7%. Over five years, NMTC leads with a -94.0% price change compared with -95.7% for BMRA. NeuroOne Medical Technologies is the larger company by market cap ($10.3 million vs $8.6 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMRA | NMTC |
|---|---|---|
| Share price | $1.87 | $1.13 |
| Market cap | $8.60M | $10.29M |
| 1-day change | 0.00% | +4.63% |
| YTD return | -25.00% | -76.25% |
| 1-year return | -34.38% | -82.69% |
| 5-year return | -95.74% | -94.00% |
| Forward P/E | 4.79 | — |
| EPS (TTM) | $-1.30 | $-0.99 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.21 | $6.42 |
| 52-week low | $1.45 | $0.962 |
| Distance from 52-week high | -41.74% | -82.40% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +543.36% |
| Average volume | 70.88K | 339.60K |
| Shares outstanding | 4.60M | 9.11M |
| Employees | 50 | 18 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BMRA has outperformed NMTC by 48.3 percentage points over the past year.
About Biomerica
BMRA stock →Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing of diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases in North America, Asia, Europe, the Middle East, and South America. The company offers diagnostic test kits are used to analyze blood, urine, nasal, or fecal material from patients to aid in the diagnosis of diseases, food intolerances, and other medical conditions, as well as detect and measure the presence and levels of specific bacteria, hormones, antibodies, antigens, and other substances that may exist in the human body at extremely low concentrations through clinical laboratories and in point-of-care settings, including physicians' offices and over-the-counter channels.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 50 employees
About NeuroOne Medical Technologies
NMTC stock →NeuroOne Medical Technologies Corporation, a medical technology company, provides solutions for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording in the United States. The company also provides solutions for spinal cord stimulation, brain stimulation, drug delivery and ablation solutions for patients suffering from epilepsy, trigeminal neuralgia, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other pain-related neurological disorders.
Health Care · Medical/Dental Instruments · 18 employees
BMRA vs NMTC FAQ
Which is bigger, Biomerica or NeuroOne Medical Technologies?
NeuroOne Medical Technologies (NMTC) is larger, with a market capitalization of $10.29M compared with $8.60M for Biomerica (BMRA).
Which stock has performed better over the past year, BMRA or NMTC?
BMRA returned -34.38% over the past 12 months, compared with -82.69% for NMTC (price return, excluding dividends). Past performance does not predict future results.
Are Biomerica and NeuroOne Medical Technologies in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: In Vitro & In Vivo Diagnostic Substances for Biomerica and Medical/Dental Instruments for NeuroOne Medical Technologies.